5 completed, 3 recruiting, 3 terminated, 2 unknown. 13 Phase 2, 4 Phase 1, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 13 | Completed 5, Recruiting 3, Terminated 3, Unknown 2 |
| Phase 1 | 4 | Recruiting 2, Completed 1, Terminated 1 |
| Phase 3 | 2 | Terminated 2 |
Follow Spasticity: new trials by email Literature Review of Spasticity trials Research Report on Spasticity
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Extracorporeal Shockwave Therapy as an Additional Treatment for Spasticity Secondary to Spinal Cord Injury Focused extracorporeal shockwave therapy, Botulinum toxin, Sham - Spinal Cord Injury, Spasticity | Phase 2 | Recruiting | Kessler Foundation | 30 | 2026-09-21 | 2026-11-04 |
| The Use of Photobiomodulation in the Treatment of Spasticity After Stroke. Photobiomodulation Therapy, Placebo PBM, Standard Multidisciplinary Rehabilitation Program for Spasticity - Stroke, Spasticity | Phase 1 / Phase 2 | Recruiting | University of Nove de Julho | 42 | 2026-08-28 | 2026-09-01 |
| Phase II Study to Assess Safety, Pharmacokinetics and Efficacy of SL-1002 for Limb Spasticity SL-1002, Placebo - Spasticity | Phase 2 | Unknown | Saol Therapeutics Inc | 32 | 2022-04-22 | 2023-09-06 |
| Efficacy and Safety Study of MYOBLOC® in the Treatment of Adult Upper Limb Spasticity Phase 2; Low Dose MYOBLOC (10,000 Units), Phase 2; High Dose MYOBLOC (20,000 Units), Phase 2; Placebo - Spasticity, Cerebrovascular Accident | Phase 2 / Phase 3 | Terminated | Solstice Neurosciences, LLC, a subsidiary of MDD US Operations, LLC | 32 | 2021-11-02 | 2026-05-27 |
| A Study to Assess the Safety and Efficacy of IPN10200 in Adult Participants With Upper Limb Spasticity. Corabotase, Placebo, Dysport - Spasticity | Phase 1 / Phase 2 | Recruiting | Ipsen | 240 | 2021-04-29 | 2026-07-28 |
| Efficacy and Safety Study of MYOBLOC® in the Treatment of Adult Lower Limb Spasticity Phase 2; Low Dose MYOBLOC (15,000 Units), Phase 2; High Dose MYOBLOC (20,000 Units), Phase 2; Placebo - Spasticity | Phase 2 / Phase 3 | Terminated | Solstice Neurosciences, LLC, a subsidiary of MDD US Operations, LLC | 40 | 2019-12-17 | 2026-05-22 |
| Developing and Testing a Comprehensive MS Spasticity Management Program Spasticity: Take Control, Usual care - Multiple Sclerosis, Spasticity | Phase 2 | Completed | VA Office of Research and Development | 40 | 2015-10-01 | 2017-03-28 |
| The Effects of Cannabis on Dystonia and Spasticity on Pediatric Patients Avidekel oil, Enriched Avidekel oil - Spasticity, Dystonia | Phase 2 | Unknown | Wolfson Medical Center | 40 | 2015-07-01 | 2015-08-18 |
| Study of SPARC1103 in Subjects With Spasticity SPARC1103 low dose, SPARC1103 high dose, SPARC Placebo - Spasticity | Phase 2 | Completed | Sun Pharma Advanced Research Company Limited | 142 | 2014-04-21 | 2019-05-03 |
| A Study to Define the ECG Effects of Tizanidine Compared to Placebo and the Positive Control, Moxifloxacin, in Healthy Men and Women Using a Blinded ECG Evaluator: A Thorough ECG Trial Tizanidine, Placebo, Moxifloxacin - Spasticity | Phase 2 | Completed | Acorda Therapeutics | 136 | 2013-04-01 | 2021-03-23 |
| A Study With IPX056 in Subjects With Spasticity Associated With Multiple Sclerosis IPX056, Baclofen IR, Placebo IPX056 - Spasticity, Multiple Sclerosis | Phase 2 | Completed | Impax Laboratories, LLC | 23 | 2009-04-01 | 2019-11-06 |
| Oral Baclofen Pharmacokinetics and Pharmacodynamics in Children With Spasticity baclofen - Spasticity, Cerebral Palsy | Phase 1 / Phase 2 | Completed | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | 61 | 2008-11-01 | 2011-12-06 |
| One Year Extension Study To Protocol C2/5/TZ:MS-05 sublingual tizanidine 12 mg - Spasticity, Multiple Sclerosis | Phase 1 / Phase 2 | Terminated | Teva GTC | 10 | 2008-01-01 | 2009-02-19 |
Muscle Spasticity (13) · Multiple Sclerosis (5) · Brain Injuries, Traumatic (3) · Cerebral Palsy (3) · Stroke (3) · Hemiplegia (2) · Dystonia (1) · Fatigue (1) · Motor Activity (1) · Spinal Cord Injuries (1)
Muscle Hypertonia (13) · Muscular Diseases (13) · Musculoskeletal Diseases (13) · Nervous System Diseases (13) · Neurologic Manifestations (13) · Neuromuscular Manifestations (13) · Pathological Conditions, Signs and Symptoms (13) · Signs and Symptoms (13) · Central Nervous System Diseases (7) · Brain Diseases (6) · Autoimmune Diseases (5) · Autoimmune Diseases of the Nervous System (5) · Demyelinating Autoimmune Diseases, CNS (5) · Demyelinating Diseases (5) · Immune System Diseases (5)
Clinical Trials, Phase II as Topic (2) · Clinical Trials, Phase III as Topic (2) · rimabotulinumtoxinB (2) · Baclofen (1) · Botulinum Toxins (1) · Low-Level Light Therapy (1) · Moxifloxacin (1) · abobotulinumtoxinA (1) · salicylhydroxamic acid (1) · tizanidine (1)
Solstice Neurosciences, LLC, a subsidiary of MDD US Operations, LLC (2) · Acorda Therapeutics (1) · Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) (1) · Impax Laboratories, LLC (1) · Ipsen (1) · Kessler Foundation (1) · Saol Therapeutics Inc (1) · Sun Pharma Advanced Research Company Limited (1) · Teva GTC (1) · University of Nove de Julho (1) · VA Office of Research and Development (1) · Wolfson Medical Center (1)
United States (10) · Hungary (3) · Poland (3) · Israel (2) · Russia (2) · Austria (1) · Brazil (1) · Bulgaria (1) · Czechia (1) · France (1) · Germany (1) · Italy (1) · Japan (1) · Portugal (1) · South Korea (1)
Joseph T Hull, PhD (2) · Arnon Karni, MD (1) · Janice Brunstrom, MD (1) · Lucinda L Hugos, MS (1) · Mathews Adera, MD (1) · Richard Stevenson, MD (1)
R21HD123083 (1)